HK1212253A1 - 用於治療糖尿病的模式的組合 - Google Patents

用於治療糖尿病的模式的組合

Info

Publication number
HK1212253A1
HK1212253A1 HK16100394.4A HK16100394A HK1212253A1 HK 1212253 A1 HK1212253 A1 HK 1212253A1 HK 16100394 A HK16100394 A HK 16100394A HK 1212253 A1 HK1212253 A1 HK 1212253A1
Authority
HK
Hong Kong
Prior art keywords
modalities
diabetes
combinations
treatment
Prior art date
Application number
HK16100394.4A
Other languages
English (en)
Inventor
Tihamer Orban
Original Assignee
Orban Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orban Biotech Llc filed Critical Orban Biotech Llc
Publication of HK1212253A1 publication Critical patent/HK1212253A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Ecology (AREA)
HK16100394.4A 2012-06-27 2016-01-14 用於治療糖尿病的模式的組合 HK1212253A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/534,571 US8735359B2 (en) 2012-05-24 2012-06-27 Combinations of modalities for the treatment of diabetes
PCT/US2013/048247 WO2014004866A1 (en) 2012-06-27 2013-06-27 Combinations of modalities for the treatment of diabetes

Publications (1)

Publication Number Publication Date
HK1212253A1 true HK1212253A1 (zh) 2016-06-10

Family

ID=49785671

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100394.4A HK1212253A1 (zh) 2012-06-27 2016-01-14 用於治療糖尿病的模式的組合

Country Status (12)

Country Link
US (5) US8735359B2 (zh)
EP (1) EP2892548A4 (zh)
JP (1) JP6552106B2 (zh)
KR (3) KR20220035146A (zh)
CN (2) CN104507490A (zh)
AU (2) AU2013284469A1 (zh)
CA (1) CA2877906C (zh)
HK (1) HK1212253A1 (zh)
IN (1) IN2015DN00215A (zh)
MX (1) MX2015000238A (zh)
WO (1) WO2014004866A1 (zh)
ZA (1) ZA201500229B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
MX2015000237A (es) 2012-06-27 2015-08-14 Orban Biotech Llc Proteinas de fusion ctla4 para el tratamiento de la diabetes.
GB2523399B (en) * 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
CN106535926B (zh) * 2014-06-04 2022-02-01 戴尔米德医疗公司 用于基于抗原的疗法的新型组合物
US20170209401A1 (en) * 2014-09-26 2017-07-27 The University Of British Columbia A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation
US20180071376A1 (en) * 2015-03-23 2018-03-15 The Brigham And Women`S Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
CN106632684A (zh) * 2016-06-01 2017-05-10 上海领潮生物科技有限公司 一种用于快速检测ⅰ型糖尿病的融合蛋白
DE102017123721A1 (de) 2017-10-12 2019-04-18 Kraussmaffei Technologies Gmbh Verfahren zur Herstellung von faserverstärkten Kunststoff-Formteilen
EP4061408A4 (en) * 2019-11-22 2024-04-10 The Research Foundation for the State University of New York COMPOSITIONS AND METHODS FOR USE IN TYPE 1 DIABETES
CN114377117B (zh) * 2021-12-06 2023-11-10 中国医学科学院医学生物学研究所 一种口服1型糖尿病疫苗及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
DE122007000078I2 (de) 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
AU687790B2 (en) * 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
US6110746A (en) 1995-06-30 2000-08-29 Yeda Research And Development Co. Ltd. Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
US7041634B2 (en) 1995-09-27 2006-05-09 Emory University Method of inhibiting immune system destruction of transplanted viable cells
US5814321A (en) 1995-11-30 1998-09-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1999051275A2 (en) * 1998-04-03 1999-10-14 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
CN101255192A (zh) 2000-05-26 2008-09-03 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SI1935427T1 (en) 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
AU2002249895A1 (en) * 2001-01-05 2002-07-16 Joslin Diabetes Center, Inc. Autoantigen composition
PT1397153E (pt) 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
CA2461543C (en) * 2001-10-24 2015-07-07 University Of Wales College Of Medicine Sperm factor sequences
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
AU2005213449A1 (en) * 2004-02-04 2005-08-25 The La Jolla Institute For Allergy And Immunology Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
CN101277722A (zh) * 2005-08-06 2008-10-01 王庆华 用于预防和治疗ⅰ型糖尿病的组合物及方法
WO2007127787A2 (en) 2006-04-25 2007-11-08 Joslin Diabetes Center, Inc. Insulin autoantigen-specific regulatory cd4+ t cells
CN101646418B (zh) * 2006-10-12 2013-07-17 昆士兰大学 调节免疫应答的组合物和方法
EP2193142B1 (en) * 2007-08-30 2015-01-07 CureDM Group Holdings, LLC Compositions and methods of using proislet peptides and analogs thereof
US9176122B2 (en) 2008-03-24 2015-11-03 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2012001647A2 (en) 2010-06-30 2012-01-05 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
WO2012015903A1 (en) 2010-07-27 2012-02-02 Bayhill Therapeutics, Inc. Treatment of type i diabetes mellitus (t1dm) in young newly diagnosed patients
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US20130316375A1 (en) 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
MX2015000237A (es) * 2012-06-27 2015-08-14 Orban Biotech Llc Proteinas de fusion ctla4 para el tratamiento de la diabetes.

Also Published As

Publication number Publication date
US20240058442A1 (en) 2024-02-22
CA2877906A1 (en) 2014-01-03
KR20150036236A (ko) 2015-04-07
IN2015DN00215A (zh) 2015-06-12
US8735359B2 (en) 2014-05-27
WO2014004866A1 (en) 2014-01-03
JP2015522027A (ja) 2015-08-03
KR20220035146A (ko) 2022-03-21
AU2018202802B2 (en) 2020-04-02
AU2018202802A1 (en) 2018-05-17
US20130315904A1 (en) 2013-11-28
US20140220015A1 (en) 2014-08-07
US20190151445A1 (en) 2019-05-23
CA2877906C (en) 2021-01-26
MX2015000238A (es) 2015-08-14
JP6552106B2 (ja) 2019-07-31
EP2892548A1 (en) 2015-07-15
ZA201500229B (en) 2015-12-23
AU2013284469A1 (en) 2015-01-29
CN113577256A (zh) 2021-11-02
US20200268883A1 (en) 2020-08-27
EP2892548A4 (en) 2016-05-25
CN104507490A (zh) 2015-04-08
KR20200142600A (ko) 2020-12-22

Similar Documents

Publication Publication Date Title
HRP20171401T1 (hr) Jednokratni uređaj za anastomozu za obrezivanje
HK1212253A1 (zh) 用於治療糖尿病的模式的組合
EP2932930A4 (en) TREATMENT INSTRUMENT
EP2906208A4 (en) THERAPEUTIC TREATMENT
GB201219873D0 (en) Diverticulitis treatment
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
EP2808018A4 (en) THERAPEUTIC AGENT FOR DIABETES
EP2883547A4 (en) MEDICINE
EP2767214A4 (en) TREATMENT INSTRUMENT
PL2875026T3 (pl) Pochodne imidazopirydyny stosowane w leczeniu cukrzycy
GB201205189D0 (en) Novel medical use
ZA201408065B (en) Compositions and methods for the treatment of diabetes
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201215502D0 (en) Medical use
IL236873A0 (en) therapeutic compounds
GB201209198D0 (en) Liquid treatment
GB201209283D0 (en) Liquid treatment
GB201211135D0 (en) Treatment
GB201208690D0 (en) Treatment
GB201212604D0 (en) New treatment
GB201215621D0 (en) Medical solution
AU344965S (en) Sideboard
GB201204645D0 (en) Treatment of disease
AU2012900513A0 (en) Avian-Based Treatment